Naga Praneeth Raja, MD
Medical Oncology · Beaverton, ORNPI 1043508757
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.9% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,674 and has fallen 97.7% since, to $38 in 2023.
Across 145 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$299
- Novartis$212
- Amgen$201
- E.r. Squibb & Sons, L.L.C.$162
- Merck$160
- Pharmacyclics LLC, An Abbvie Company$145
- plus $989 from 23 others
Across 2 payments — averaging $349.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$500
- Pfizer$199
What the payments were for
- Food & beverage$1,99192%
- Education$1768%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $299 |
| Novartis | 15 | $212 |
| Amgen | 11 | $201 |
| E.r. Squibb & Sons, L.L.C. | 18 | $162 |
| Merck | 13 | $160 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $145 |
| Eisai Inc. | 6 | $109 |
| Seagen Inc. | 5 | $83 |
| Puma Biotechnology, Inc. | 4 | $65 |
| Pfizer | 4 | $59 |
| Bristol Myers Squibb | 4 | $54 |
| Sanofi | 3 | $50 |
| Verastem, Inc. | 3 | $47 |
| Bayer | 4 | $46 |
| Boehringer Ingelheim | 3 | $46 |
| Genentech USA, Inc. | 4 | $46 |
| Tesaro, Inc. | 3 | $44 |
| Exelixis Inc. | 3 | $39 |
| Taiho Oncology, Inc. | 3 | $38 |
| Incyte Corporation | 2 | $33 |
| Astellas Pharma US Inc | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Clovis Oncology, Inc. | 2 | $28 |
| Lilly USA, LLC | 2 | $27 |
| Foundation Medicine, Inc. | 2 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Beigene USA, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$2,167 in reported general payments places this provider in the 60th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 12 | $149,663 |
| EliquisApixaban | 15 | $16,650 |
| Abiraterone Acetate | 30 | $15,492 |
| Prochlorperazine Maleate | 45 | $995 |
| Dexamethasone | 59 | $654 |
| Tamoxifen Citrate | 26 | $653 |
| Letrozole | 32 | $622 |
| Hydroxyurea | 17 | $443 |
| Oxycodone Hcl | 33 | $421 |
| Ondansetron OdtOndansetron | 16 | $297 |
| Anastrozole | 23 | $276 |
| Olanzapine | 15 | $207 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $201 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $160 |
| Acyclovir | 26 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $16,65015 claims |
| Lilly USA, LLCOlanzapine | $27 | $20715 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $14 | $14726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 92 medical oncology providers in Oregon.
Other medical oncology in Beaverton
- Jeff SharmanEugene$264K
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.